![]() | |
Clinical data | |
---|---|
Trade names | Duvyzat |
AHFS/Drugs.com | Monograph |
MedlinePlus | a624025 |
License data |
|
Routes of administration | By mouth |
Drug class | Histone deacetylase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.258.524 |
Chemical and physical data | |
Formula | C24H27N3O4 |
Molar mass | 421.497 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Givinostat, sold under the brand name Duvyzat is a medication used for the treatment of Duchenne muscular dystrophy.[1][2] It is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities.[3] It is a histone deacetylase (HDAC) inhibitor that works by targeting pathogenic processes to reduce inflammation and loss of muscle.[2]
The most common side effects include diarrhea, abdominal pain, low platelets (thrombocytopenia), nausea/vomiting, an increase in triglycerides (a type of fat in the body) (hypertriglyceridemia), and fever.[2][4]
Givinostat was approved for medical use in the United States in March 2024.[2][5] Givinostat is the first nonsteroidal medication approved by the US Food and Drug Administration (FDA) to treat people with all genetic variants of Duchenne muscular dystrophy.[2]
Duvyzat FDA snapshot
was invoked but never defined (see the help page).